eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to access mRNA technologies

Post Views: 144 eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing…